Article title: Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial
Authors: Caroline Hedsund, Kasper Linde Ankjærgaard, Tine Peick Sonne, Philip Tønnesen, Ejvind Frausing Hansen, Helle Frost Andreassen, Ronan M. G. Berg, Jens-Ulrik Stæhr Jensen and Jon Torgny Wilcke
Journal: European Clinical Respiratory Journal
Bibliometrics: Volume 10, Number 1, pages 1-11
DOI: https://doi.org/10.1080/20018525.2023.2257993
The author has discovered an error related to one of the health-related quality of life measurements reported in the published article. The error occurred during the recoding of patient-reported Severe Respiratory Insufficiency Questionnaire (SRI) items for analysis.
This has impacted Tables 1 and 4. The updated tables are provided below. These corrections do not affect the description, interpretation, or original conclusions of the article. The authors apologize for any inconvenience caused.
Table 1:
Baseline characteristics and index admission data for patients included in the Intention-To-Treat (ITT) analysis, presented as median (IQR) unless otherwise stated.
| Baseline characteristics | n | ITT |
|
|---|---|---|---|
| LT-NIV (n=28) | Control (n=27) | ||
| Age, years, | 55 | 70 (66-75) | 73 (64-77) |
| Female Sex, n (%) | 55 | 16 (57%) | 13 (48%) |
| Body mass index (BMI), kg/m2 | 52 | 27.7 (21.7-32.8) | 21.8 (19.1-26.6) |
| Long-term oxygen treatment (LTOT), n (%) | 55 | 14 (50%) | 16 (59%) |
| Pack years | 54 | 46 (35-50) | 50 (30-55) |
| Smoking history, n (%) | 55 | ||
| - Current | 13 (46%) | 11 (41%) | |
| - Previous | 15 (54%) | 15 (56%) | |
| - Never | 0 (0%) | 1 (4%) | |
| Forced expiratory volume, first second of expiration (FEV1), liter | 54 | 0.6 (0.5-0.8) | 0.6 (0.5-0.8) |
| FEV1, % predicted | 54 | 24 (21-30) | 28 (18-33) |
| Forced vital capacity (FVC), liter | 54 | 1.4 (1.1-1.9) | 1.7 (1.4-2.0) |
| FVC, % predicted | 53 | 44 (41-53) | 51 (43-67) |
| FEV1/ FVC ratio | 54 | 0.4 (0.4-0.5) | 0.4 (0.3-0.4) |
| COPD related medication, n (%) | 55 | ||
| - Long-acting muscarinic antagonist (LAMA) | 27 (96%) | 24 (89 %) | |
| - Long-acting beta2 agonist (LABA) | 27 (96%) | 27 (100%) | |
| - Inhalation corticosteroids (ICS) | 19 (68%) | 23 (85%) | |
| - Oral corticosteroids (OCS) | 2 (7%) | 2 (7%) | |
| - Theophylline | 4 (14%) | 1 (4%) | |
| - Roflumilast | 3 (11%) | 2 (7%) | |
| - Azithromycin | 3 (11%) | 1 (4%) | |
| No. Moderate AECODP last year | 55 | 2 (1-4) | 2 (0-4) |
| No. admissions respiratory cause last year | 55 | 1 (0-4) | 1 (0-3) |
| No. admissions with AHRF last year | 55 | 0 (0-1) | 0 (0-1) |
| ≥ 2 AHRF last year, n (%) | 55 | 13 (46%) | 10 (37%) |
| Comorbidities n (%) | 55 | ||
| - Heart failure | 8 (29%) | 6 (22%) | |
| - Osteoporosis | 12 (43%) | 7 (26%) | |
| - Depression | 5 (18%) | 5 (19%) | |
| Medical Research Council dyspnoea score (MRC) | 53 | 4 (3-4) | 4 (3-4) |
| Severe Respiratory Insufficiency questionnaire (SRI) | 50 | 50.9 (38.6 – 58.3) | 50.8 (44.1 – 55.8) |
| COPD Assessment Test (CAT) | 53 | 22 (15-25) | 20 (15-26) |
| Epworth sleepiness scale (ESS) | 52 | 9 (5-11) | 6 (3-10) |
| Index admission data | |||
| Length of hospital stay, days | 52 | 7 (5-11) | 6 (4-10) |
| Blood gas at admission, before initiation of acute NIV | |||
| - Partial arterial carbon dioxide pressure (PaCO2), kPa | 55 | 10.0 (8.6-11.3) | 9.0 (7.9-10.5) |
| - Partial arterial oxygen pressure (PaO2), kPa | 55 | 10.2 (8.2-12.6) | 9.9 (8.0-11.5) |
| - pH | 55 | 7.29 (7.23-7.32) | 7.28 (7.25-7.32) |
| - Oxygen saturation (SaO2) (%) | 53 | 92 (89-95) | 92 (90-95) |
| - Standard bicarbonate (StHCO3) | 53 | 27.5 (24.3-33.3) | 28.5 (25.6-31.8) |
| - Base Excess (BE) | 52 | 6.0 (2.6-8.8) | 5.8 (3.2-10.0) |
| Blood gas at discharge | |||
| - PaCO2 (kPa) | 50 | 6.9 (6.3-7.6) | 6.9 (6.1-7.5) |
| - PaO2 (kPa) | 49 | 7.9 (7.4-9.1) | 8.9 (7.2-10.6) |
| - pH | 50 | 7.43 (7.41-7.45) | 7.42 (7.39-7.45) |
| - SaO2 | 49 | 92 (90-94) | 93 (90-96) |
| - StHBO3 | 49 | 31.5 (30.1-34.2) | 30.8 (28.7-32.9) |
| - BE | 48 | 8.7 (6.6-12.1) | 8.3 (5.4-11.4) |
| PaCO2 ≤ 6.0 kPa at discharge, n (%) | 50 | 4 (16%) | 8 (30%) |
| NIV maximum pressures, cmH2O | |||
| - Inspiratory positive airway pressure (IPAP) | 47 | 21 (18-24) | 18 (16-22) |
| - Expiratory positive airway pressure (EPAP) | 47 | 5 (5-6) | 5 (5-6) |
Table 4:
Secondary outcomes, including change from baseline in absolute values. Forced expiratory volume within first second of expiration (FEV1 %), Body mass index (BMI), Medical Research Council dyspnoea score (MRC), COPD Assessment Test (CAT), Severe Respiratory Insufficiency questionnaire (SRI), Epworth sleepiness scale (ESS). PP: patients included in the per protocol analysis. Presented as median (IQR) Analysis: Wilcoxon test
| PP: 90 days follow up |
PP: 365 days follow up |
|||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (discharge) |
At 90 days | Change within 90 days | n | Baseline (discharge) |
At 1 year | Change within 1 year | n | |
| FEV1 % | ||||||||
| - LT-NIV | 24 (20-32) | 24 (19-45) | -1.0 (-7.0 – 2.0) | 18 | 24 (21-34) | 35 (27-55) | -3.0 (-12.5 – -0.6) | 11 |
| - Control | 29 (20-34) | 26 (19-29) | 1.4 (-1.9 – 4.1) | 13 | 29 (18-35) | 23 (15-35) | -0.4 (-2.6 – 2.0) | 7 |
| p | 0.816 | 0.574 | 0.237 | 0.796 | 0.112 | 0.202 | ||
| BMI | ||||||||
| - LT-NIV | 27.8 (21.2-33.6) | 27.5 (24.4-32.1) | -0.4 (-1.8 – 0.6) | 18 | 27.8 (20.1-34.4) | 30.9 (27.4-33.7) | 0.1 (-2.4 – 3.0) | 10 |
| - Control | 22.9 (20.0-27.2) | 24.1 (19.8-27.0) | -0.1 (-1.1 – 0.9) | 13 | 21.8 (18.8-26.6) | 26.7 (21.5-28.6) | -1.3 (-2.4 – 1.7) | 7 |
| p | 0.113 | 0.051 | 0.275 | 0.128 | 0.043 | 0.601 | ||
| MRC | ||||||||
| - LT-NIV | 4 (3-5) | 3 (3-4) | 1(0-1) | 19 | 4 (3-5) | 3 (3-5) | 0 (0 – 1) | 13 |
| - Control | 4 (3-4) | 3 (3-4) | 1(0-1) | 13 | 4 (3-4) | 3 (3-4) | 0 (-1 – 1) | 7 |
| p | 0.523 | 0.391 | 0.647 | 0.148 | 0.881 | 0.901 | ||
| CAT | ||||||||
| - LT-NIV | 22 (16-25) | 19 (10-27) | 2(-1 – 7) | 19 | 22 (16-25) | 15 (12-22) | 2 (-3 – 8) | 11 |
| - Control | 20 (16-26) | 18 (15-20) | 4 (-2 - 8) | 13 | 23 (20-27) | 20 (16-28) | 4 (-8 – 8) | 7 |
| p | 0.874 | 0.872 | 0.711 | 0.561 | 0.205 | 0.893 | ||
| SRI | ||||||||
| - LT-NIV | 50.4 (36.4 – 59.1) | 58.6 (34.0 – 64.2) | -3.1 (-14.5 – 5.8) | 19 | 51.1 (38.9 – 59.7) | 59.9 (50.4 – 71.9) | -7.2 (-13.6 – 2.0) | 11 |
| - Control | 50.9 (43.8 – 56.4) | 48.0 (45.8 – 69.1) | -5.3 (-14.6 – 2.8) | 12 | 51.9 (45.2 – 56.5) | 56.2 (42.5 – 59.6) | -1.0 (-5.1 – 6.6) | 7 |
| p | 0.264 | 0.904 | 0.369 | 0.179 | 0.424 | 0.456 | ||
| ESS | ||||||||
| - LT-NIV | 8 (4-11) | 4 (2-9) | 2 (-3 – 6) | 19 | 8 (5-11) | 6 (1-9) | 0 (-1 – 6) | 11 |
| - Control | 7 (3-9) | 3 (2-6) | 1 (-1 – 3) | 13 | 5 (4-9) | 2 (2-8) | 2 (0-4) | 7 |
| p | 0.351 | 0.730 | 0.696 | 0.221 | 0.561 | 0.828 | ||